Wave Life Sciences' Robust 2026 Pipeline to Support Outlook, Wedbush Says

MT Newswires Live12-12 23:25

Wave Life Sciences' (WVE) PRISM technology platform is expected to support a robust pipeline for 2026 and its outlook, Wedbush said in a note Friday, adding the stock to its "Best Ideas List."

The upcoming WVE-007 higher-dose readouts in Q1 and Q2 2026, a WVE-006 update in alpha-1 antitrypsin deficiency in Q1 2026, and an expected New Drug Application submission for WVE-N531 in Duchenne muscular dystrophy, are expected to support the company's numbers going forward, the investment firm said.

Wedbush said it raised its probability-of-success estimate for WVE-007 to 50% from 25% and models it as a potential monotherapy in obesity in addition to an add-on approach with GLP-1 therapies.

Wedbush's 2035 worldwide revenue view for WVE-007 is $8.3 billion across monotherapy and add-on use, up from a prior $2.5 billion estimate focused on add-on use alone, according to the note.

WVE-006 is also part of the company's broader validation case for Wave's RNA editing approach, including a possible 2026 clinical trial application submission for WVE-008 targeting PNPLA3 I148M liver disease, Wedbush analysts noted.

Wedbush maintained an outperform rating for the company and raised its price target to $33 from $20.

Price: 16.88, Change: +0.13, Percent Change: +0.78

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590507751?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-12 23:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590507751","market":"nz","top_or_hot":-1,"title":"Wave Life Sciences' Robust 2026 Pipeline to Support Outlook, Wedbush Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/WVE\">Wave Life</a> Sciences' (WVE) PRISM technology platform is expected to support a robust pipeline for 2026 and its outlook, Wedbush said in a note Friday, adding the stock to its \"Best Ideas List.\"</p><p>The upcoming WVE-007 higher-dose readouts in Q1 and Q2 2026, a WVE-006 update in alpha-1 antitrypsin deficiency in Q1 2026, and an expected New Drug Application submission for WVE-N531 in Duchenne muscular dystrophy, are expected to support the company's numbers going forward, the investment firm said.</p><p>Wedbush said it raised its probability-of-success estimate for WVE-007 to 50% from 25% and models it as a potential monotherapy in obesity in addition to an add-on approach with GLP-1 therapies.</p><p>Wedbush's 2035 worldwide revenue view for WVE-007 is $8.3 billion across monotherapy and add-on use, up from a prior $2.5 billion estimate focused on add-on use alone, according to the note.</p><p>WVE-006 is also part of the company's broader validation case for Wave's RNA editing approach, including a possible 2026 clinical trial application submission for WVE-008 targeting PNPLA3 I148M liver disease, Wedbush analysts noted.</p><p>Wedbush maintained an outperform rating for the company and raised its price target to $33 from $20.</p><p>Price: 16.88, Change: +0.13, Percent Change: +0.78</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wave Life Sciences' Robust 2026 Pipeline to Support Outlook, Wedbush Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWave Life Sciences' Robust 2026 Pipeline to Support Outlook, Wedbush Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-12 23:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/WVE\">Wave Life</a> Sciences' (WVE) PRISM technology platform is expected to support a robust pipeline for 2026 and its outlook, Wedbush said in a note Friday, adding the stock to its \"Best Ideas List.\"</p><p>The upcoming WVE-007 higher-dose readouts in Q1 and Q2 2026, a WVE-006 update in alpha-1 antitrypsin deficiency in Q1 2026, and an expected New Drug Application submission for WVE-N531 in Duchenne muscular dystrophy, are expected to support the company's numbers going forward, the investment firm said.</p><p>Wedbush said it raised its probability-of-success estimate for WVE-007 to 50% from 25% and models it as a potential monotherapy in obesity in addition to an add-on approach with GLP-1 therapies.</p><p>Wedbush's 2035 worldwide revenue view for WVE-007 is $8.3 billion across monotherapy and add-on use, up from a prior $2.5 billion estimate focused on add-on use alone, according to the note.</p><p>WVE-006 is also part of the company's broader validation case for Wave's RNA editing approach, including a possible 2026 clinical trial application submission for WVE-008 targeting PNPLA3 I148M liver disease, Wedbush analysts noted.</p><p>Wedbush maintained an outperform rating for the company and raised its price target to $33 from $20.</p><p>Price: 16.88, Change: +0.13, Percent Change: +0.78</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2590507751","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590507751","pubTimestamp":1765553109,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Wave Life Sciences'  PRISM technology platform is expected to support a robust pipeline for 2026 and its outlook, Wedbush said in a note Friday, adding the stock to its \"Best Ideas List.\"The upcoming WVE-007 higher-dose readouts in Q1 and Q2 2026, a WVE-006 update in alpha-1 antitrypsin deficiency in Q1 2026, and an expected New Drug Application submission for WVE-N531 in Duchenne muscular dystrophy, are expected to support the company's numbers going forward, the investment firm said.Wedbush said it raised its probability-of-success estimate for WVE-007 to 50% from 25% and models it as a potential monotherapy in obesity in addition to an add-on approach with GLP-1 therapies.Wedbush's 2035 worldwide revenue view for WVE-007 is $8.3 billion across monotherapy and add-on use, up from a prior $2.5 billion estimate focused on add-on use alone, according to the note.WVE-006 is also part of the company's broader validation case for Wave's RNA editing approach, including a possible 2026 clini","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","WVE":"Wave Life Sciences Pte. Ltd"},"translate_title":"Wedbush表示，Wave Life Sciences强大的2026年产品线将支持前景","themeId":"d86fc1a050ef35f0b0e63806145f697e","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"WVE":1},"content_text":"Wave Life Sciences' (WVE) PRISM technology platform is expected to support a robust pipeline for 2026 and its outlook, Wedbush said in a note Friday, adding the stock to its \"Best Ideas List.\"The upcoming WVE-007 higher-dose readouts in Q1 and Q2 2026, a WVE-006 update in alpha-1 antitrypsin deficiency in Q1 2026, and an expected New Drug Application submission for WVE-N531 in Duchenne muscular dystrophy, are expected to support the company's numbers going forward, the investment firm said.Wedbush said it raised its probability-of-success estimate for WVE-007 to 50% from 25% and models it as a potential monotherapy in obesity in addition to an add-on approach with GLP-1 therapies.Wedbush's 2035 worldwide revenue view for WVE-007 is $8.3 billion across monotherapy and add-on use, up from a prior $2.5 billion estimate focused on add-on use alone, according to the note.WVE-006 is also part of the company's broader validation case for Wave's RNA editing approach, including a possible 2026 clinical trial application submission for WVE-008 targeting PNPLA3 I148M liver disease, Wedbush analysts noted.Wedbush maintained an outperform rating for the company and raised its price target to $33 from $20.Price: 16.88, Change: +0.13, Percent Change: +0.78","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590507751","isCrawlerRequest":true}